Hyperbaric Oxygen Therapy (HBOT) Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy describes coverage and medical necessity criteria for systemic hyperbaric oxygen therapy and states that topical HBOT is investigational; it applies to Blue Cross Blue Shield - North Carolina members and providers adjudicating benefits.
When covered section updated to include avascular necrosis (aseptic osteonecrosis) as an indication for coverage based on updated UHMS guidelines.
Updated wording replacing 'patients' with 'individuals' in coverage criteria.
HCPCS code G0277 was added to the Billing/Coding section effective 1/1/15.
Coverage and Medical Necessity Criteria
Covered indications for systemic HBOT
Systemic HBOT is covered when the medical criteria below are met for the listed conditions.
List directly from policy.
Diabetic lower extremity wound criteria (subset requiring AND logic)
Covered for diabetic lower extremity wounds when ALL of the following are met:
Policy explicitly lists these three required elements.
Evidence summaries and indication updates
Evidence-based coverage statements and recent indication updates relevant to HBOT coverage are summarized below.
Summary of evidence from policy guidelines.
Summary of evidence from policy guidelines.
Summary of evidence from policy guidelines.
Summary of evidence from policy guidelines.
Summary of evidence from policy guidelines.
Policy implementation/update information.
Topical hyperbaric oxygen therapy is considered investigational and is not covered by BCBSNC.
Hyperbaric oxygen therapy for indications not listed as covered in this policy is considered investigational and is not covered.
Topical hyperbaric oxygen therapy is addressed in a separate policy (see MED1431); historical policy updates have repeatedly distinguished topical HBOT from systemic pressurization and have listed multiple indications as investigational in prior implementation notes.
Any use of topical HBOT, and uses of HBOT for conditions not explicitly listed as covered in this policy, are considered investigational/not medically necessary and will not be authorized for coverage.
Systemic HBOT has been studied for several indications with mixed or insufficient evidence. Randomized trials and systematic reviews report short‑term symptom relief for migraine but lack longer‑term outcome data; an unblinded RCT of herpes zoster reported only short‑term (6‑week) outcomes; small, methodologically limited trials exist for fibromyalgia; Cochrane review data do not show benefit for multiple sclerosis; and cancer studies report inconsistent tumor control findings with significant adverse events and no demonstrated survival benefit. For these indications the evidence is insufficient to conclude an improvement in net health outcome.
Billing and Coding
Provider Responsibilities, Documentation, and Prior Authorization
Prior authorization required for systemic HBOT
Systemic HBOT requires prior authorization demonstrating that the medical necessity criteria in this policy are met before coverage will be provided. Topical hyperbaric oxygen therapy is investigational and is not authorized or covered.
- Prior authorization must document that all applicable medical necessity elements for the requested indication are satisfied.
List applicable service codes and expect documentation requests
Include applicable service codes on submissions but note that listing a code does not guarantee reimbursement; BCBSNC may request medical records to determine medical necessity when these codes are billed.
Step therapy: document prior standard wound therapy trial before HBOT
For diabetic lower-extremity (foot) ulcers, ensure the member has undergone an adequate trial of standard wound therapy and shown inadequate healing before submitting for HBOT; guideline references indicate trials ranging from a minimum of 4 days to 30 days depending on context, with policy requiring 30 days without measurable healing.
- Policy requirement: no measurable signs of healing after 30 days of an adequate course of standard wound therapy for diabetic lower extremity wounds (Wagner ≥3).
- Guideline: adjunctive HBOT is recommended when ulcers fail to improve after a minimum of 4 weeks (≥50% area reduction) and suggested after 4–6 weeks of conservative management.
Provide complete records when requested
Provide complete wound and diabetes information in the record; incomplete or missing required data may prevent a medical necessity determination.
- When medical records are requested, letters alone are often useful but are not sufficient unless they include all specific information needed to make a medical necessity determination.
Required wound documentation for diabetic lower‑extremity wounds
Document the patient’s diabetes type, the Wagner grade of the wound, and evidence showing no measurable signs of healing after an adequate 30‑day course of standard wound therapy.
- Required documentation: diabetes type (Type I or II), wound classified as Wagner grade 3 or higher, and documentation showing no measurable healing after 30 days of adequate standard wound care.
Medical record content required when records are requested
When BCBSNC requests medical records to determine medical necessity, include all specific clinical data (e.g., wound measurements, duration and type of prior therapies, Wagner grade, diabetes type); letters of support alone are insufficient unless they contain the full required information.
- Include wound measurements, dates and descriptions of prior standard wound therapy, and objective evidence of lack of healing.
- Letters of support or explanation are not sufficient unless they include all specific information needed for a medical necessity determination.
Topical HBOT is investigational — will be denied
Requests for topical hyperbaric oxygen therapy will be denied because topical HBOT is considered investigational and is not covered under this policy.
- Topical Hyperbaric Oxygen Therapy is investigational for all indications and BCBSNC does not cover investigational services.
Deny when medical necessity criteria are not met
Deny systemic HBOT requests that do not meet the policy’s medical necessity criteria — for example, diabetic lower-extremity wounds that are Wagner grade <3 or lack documentation of no measurable healing after 30 days of standard wound therapy.
- Examples warranting denial: Wagner grade less than 3; absence of documentation of a 30‑day inadequate response to standard wound therapy; missing objective wound measurements.
Missing or incomplete documentation may trigger denial
If the requested records do not include the specific information needed to determine medical necessity (wound grade, diabetes type, documentation of prior therapy and lack of healing), BCBSNC may deny the request after review.
- Absence of required data (Wagner grade, diabetes type, 30‑day inadequate healing documentation) may lead to denial when records are reviewed.
Background and Rationale
Hyperbaric oxygen therapy delivers elevated oxygen pressures either systemically inside a pressure chamber or topically to an enclosed wound area. Systemic HBOT involves enclosing the patient in a chamber and administering oxygen at pressures above atmospheric to increase oxygen delivery via the circulation. Topical HBOT delivers 100% oxygen directly to an open, moist wound at slightly above atmospheric pressure; topical HBOT is considered investigational and is managed under a separate policy. Adverse events from systemic HBOT are uncommon (approximately 0.4%) but can include barotrauma and oxygen toxicity affecting pulmonary, neurologic, and ophthalmologic systems.
Key Definitions
Policy History and Updates
When Covered section updated to add avascular necrosis (aseptic osteonecrosis) as an indication for systemic HBOT based on updated Undersea and Hyperbaric Medical Society guidance; references and policy guidelines updated.
Regulatory status updated and wording in coverage criteria modernized (replaced 'patients' with 'individuals'); references updated.
HCPCS code G0277 was added to the Billing/Coding section effective 01/01/2015.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.